Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

During this educational Tumor Board, breast cancer specialists will showcase challenging scenarios in metastatic and non-metastatic HR+ disease and contextualize data from pivotal clinical trials to optimize decision-making for patients with HR+/HER2- breast cancer.

Featuring: 
Fátima Cardoso, MD

Director, Breast UnitChampalimaud Clinical CenterLisbon, Portugal
Mario Campone, MD, PhDChief Executive OfficerInstitut de Cancérologie de l’Ouest (ICO)Angers, France
Giuseppe Viale, MD, FRCPathChairmanDepartment of PathologyUniversity of MilanMilan, Italy 

Dr. Eden Miller and Kim Zuber, PA-C, discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties. After you listen to this podcast, go to https://www.gotoper.com/2022consckd to learn more and get CME credit!

Featuring:
Eden Miller, DO

High Lakes Health Care SistersSisters, OR
Kim Zuber, PA-CExecutive Director, American Academy of Nephrology Physician AssistantsSt. Petersburg, FL

Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs to know about this emerging therapy as it makes it’s way out of clinical trials and into the clinic. 

Featuring:
Omid Hamid, MD
Cedars-Sinai CANCER
Los Angeles, CA